Stereotactic radiotherapy combined with chemotherapy of etoposide-cisplatin for elderly limited-stage small-cell lung cancer in 23 cases

• DOI: 10.3760/cma.j.issn.1674-4756.2010.02.002
• Publication Date: 2010-01-25
• Authors: Yu-long Duan; Qingguo Liu; FANXiang-hui; Hongtao He; ZHAOCheng; Hong-quan Xie; DINGZhao-peng

Objective To evaluate of stereotactic radiotherapy(SRT) combined with chemotherapy in etoposide -cisplatin for elderly limited-stage small-cell lung cancerr(LD-SCLC). Methods Twenty three cases patients LD-SCLC were treated by SRT(prescription dose was 56 -72 Gy, a median 60.8 Gy) and (EP: cisplatin 20 mg d1-5, E: 100 d 1-5, weeks cycle. For two to four cycles). Results The local control rate (CR + PR) 82.5%, the 1,2 year survival rates 67.8% 29.0% respectively,with time 13.1 months. frequencies 19%, distant metastasis 43%. Conclusions SRT etoposide-cisplatin cancer could be more effectively, tolerate side effects.

Key words: Small-cell ; Elderly Radiotherapy Chemotherapy Stereotactic radiotherapy ;